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Abstract Treatment with glucocorticoid (GC) is the preferred
therapy for polymyalgia rheumatica (PMR), but some patients
show poor responses to the initial GC regimen or experience
flares on GC tapering. Alternative therapies for patients with
GC resistance have not yet been established. To evaluate
pretreatment characteristics and therapeutic outcomes of GC-
resistant PMR, we followed all patients who had been diag-
nosed with PMR between October 2007 and February 2013,
according to our standardized protocol. GC-resistant patients
were defined as those who had responded poorly to the initial
GC regimen (15 mg/day of prednisolone) or those who had
responded to the initial regimen but had experienced a flare
upon GC tapering to 5 mg/day of the maintenance dose or
within the first 6 months of maintenance therapy. Out of 23
patients, nine were found to be GC-resistant cases and the
others were GC responders. Baseline values of PMR activity
score and its components, especially the ability to elevate the
upper limbs (EUL), were significantly higher in GC-resistant
patients compared with GC responders. The additional use of
methotrexate (MTX, five cases), salazosulfapyridine (one
case), and tocilizumab (TCZ, three cases) was effective for
GC-resistant patients, although 13 to 39 weeks were required
for the achievement of remission. We report the three GC-
resistant cases in which TCZ was added to GC therapy with or
without MTX. We also review the medical literature on the
use of TCZ as of January 31, 2014 and discuss the utility of
TCZ in the treatment of GC-resistant PMR.
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Introduction
Polymyalgia rheumatica (PMR) is an inflammatory condition
of unknown etiology that is characterized by pain and morn-
ing stiffness in the neck, shoulder, and pelvic girdles. It affects
people over 50 years of age. Constitutional symptoms such as
low-grade fever, fatigue, and weight loss, as well as increased
levels of acute inflammatory reactants, are present in most
patients [1]. Although the proximal symptoms are prominent,
distal musculoskeletal manifestations are also frequently ob-
served in PMR patients [2]. Articular and periarticular syno-
vitis appears to be commonly and primarily responsible for the
proximal and distal musculoskeletal symptoms of PMR [3].
Usually, PMR is dramatically improved with a once-daily
low dose of glucocorticoids (GCs). Clinical symptoms resolve
completely or nearly completely within one to a few days in
response to 15- to 20-mg daily prednisolone or equivalent,
and acute inflammatory reactants are normalized within
4 weeks [4]. However, approximately half of PMR patients
experience a flare of disease activity upon GC tapering or
discontinuation [5–7]. Patients with a chronic, repeated re-
lapsing course may require GC therapy for several years,
which can cause undesirable GC-related adverse events such
as osteoporotic fracture, diabetes mellitus, hypertension, in-
fections, gastrointestinal bleeding, and other conditions. A
population-based study showed that approximately 65 % of
PMR patients had at least one GC-related serious adverse
event [8]. In addition, some patients have only a partial
response or do not respond to the initial GC regimen.
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Hutchings et al. reported that 55 % of patients showed poor or
partial response to 3-week GC therapy [9]. Currently, it is
difficult to predict which patients are most at risk for devel-
oping such GC resistance.
Furthermore, as there are no guidelines for the management
of GC-resistant PMR patients, alternative therapies may be
considered. Immunosuppressive agents such as methotrexate
(MTX) and biological agents such as anti-tumor necrosis
factor-α (anti-TNFα) agents and anti-interleukin-6 (anti-IL-
6) receptor antibody tocilizumab (TCZ) may be possible
candidates as adjunctive therapies.
In this study, we followed all patients who had been diag-
nosed with PMR at our hospital from October 2007 to
February 2013, according to our standardized protocol for
PMR management, and evaluated pretreatment clinical fea-
tures and therapeutic outcomes of GC-resistant cases. Among
these cases, we report three patients who achieved remission
by the addition of TCZ. We also review the medical literature
on TCZ use for PMR that was isolated through a search of the
PubMed database as of January 31, 2014.
Patients and methods
Patients
We followed all patients who had been diagnosed with PMR
at our hospital fromOctober 2007 to February 2013 according
to our PMR management protocol. Diagnosis had been made
on the basis of Bird’s criteria for PMR [10].We confirmed that
all patients fulfilled the 2012 provisional classification criteria
for PMR by the European League Against Rheumatism
(EULAR) and the American College of Rheumatology
(ACR) [1]. There were no clinical symptoms or signs to raise
clinical suspicion of giant cell arthritis (GCA), other systemic
vascul i t is , rheumatoid arthr i t is , or seronegat ive
spondylarthropathy. There was no muscle weakness or atro-
phy. Peripheral joint involvement was seen in four patients.
Rheumatoid factor (RF), anti-citrullinated peptide antibodies
(anti-CCP Abs), antinuclear antibodies (ANAs), and anti-
neutrophil cytoplasmic antibodies (ANCAs) were all nega-
tive. No increases in muscular enzymes were detected. No
patients had any clinical evidence suggesting active cancer or
infectious disease. Inflammatory markers were determined at
presentation and every 2 to 4 weeks during the follow-up
period. All patients were followed for at least 1 year.
Protocol of PMR management
All PMR patients were treated at our hospital according to the
following protocol for PMR management. Patients started
with an initial regimen of 15 mg of prednisolone daily as a
single morning dose. To evaluate pretreatment factors
associated with the development of GC resistance, the fixed
initial dose was used for all patients. Based on data from the
only randomized controlled studies on initial prednisolone
doses, we determined 15 mg/day of prednisolone as the initial
regimen [11, 12]. After 2 to 3 weeks, the daily dose was
reduced by 2.5 mg every 2 weeks to 10 mg/day as long as
symptoms remained improved. The daily dose was then ta-
pered by 1 to 2 mg every month until a maintenance dosage of
5 mg/daywas reached if remission persisted. Themaintenance
therapy was continued for at least 6 months. Further reduction
and suspension of GCwere left to the discretion of the treating
rheumatologist. If the patient did not respond to the initial GC
regimen and no alternative diagnosis was made, the addition
of other immunosuppressive agents was considered. If the
patient experienced a flare on tapering to the maintenance
dose of 5 mg/day, the addition of other immunosuppressive
agents was considered. If the patient experienced a flare when
reducing the prednisolone dose below 5 mg/day, an increase
to the previously effective dosage was made.
Definition of GC resistance
GC responders were defined as patients who had responded
well to the initial GC dose, tolerated a reduction to the mainte-
nance dose of 5 mg/day, and thereafter maintained remission
for at least 6 months. GC-resistant patients were defined as
those who had responded poorly to the initial GC regimen or
those who had responded to the initial regimen but had expe-
rienced a flare upon GC tapering to the maintenance dose of
5 mg/day or within the first 6 months of the maintenance
therapy. A flare was defined as an exacerbation or reappearance
of PMR symptoms (aching and stiffness at the shoulder girdle,
pelvic girdle, or both) associated with abnormal C-reactive
protein (CRP, >0.5 mg/dl) level, erythrocyte sedimentation rate
(ESR, >30mm/h), or both. Remission was defined as achieving
a PMR activity score (PMR-AS) of 0 to 1.5 [13].
Calculation of PMR-AS
The PMR-AS was calculated according to the equation
CRP (mg/dl) + the visual analog scale for pain (VAS-p,
0–10) + the visual analog scale for physician’s assessment
(VAS-ph, 0–10) + morning stiffness (MST, min) × 0.1 + ability
to elevate the upper limbs (EUL, 0–3) [14].
Clinical characteristics of GC-resistant PMR patients
Fourteen patients were GC responders and nine were GC-
resistant. No GC-related severe adverse events were seen
during the follow-up period. All GC responders achieved
remission within 2 to 6 weeks and maintained it for more than
6 months. Among these patients, seven maintained remission
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for more than 6 months without prednisolone. In GC-resistant
patients, three did not respond to the initial GC regimen and
six did not tolerate GC tapering. The addition of MTX and
salazosulfapyridine (SASP) was effective for five and one
patients, respectively, though 13 to 32 weeks were required
for the achievement of remission. Among these six patients,
three successfully discontinued all agents for PMR therapy
and maintained remission for more than 6 months. The other
three maintained remission for more than 6 months with 5 mg/
day of prednisolone. The remaining three patients received
TCZ with or without MTX (see next section). Clinical char-
acteristics of GC responders and GC-resistant patients at
baseline are shown in Table 1. Pretreatment values of the
PMR-AS and its components, especially EUL, were signifi-
cantly higher in GC-resistant patients compared with GC
responders. In addition, GC-resistant patients were more like-
ly to take a longer time to achieve first remission.
Case reports of GC-resistant and TCZ-treated PMR
We present three GC-resistant PMR patients who received
TCZ therapy. Cases 1 and 2 were MTX-resistant and SASP-
resistant PMR, respectively. In case 3, PMR signs and symp-
toms were markedly aggravated during the initial GC therapy.
Case 1
A 55-year-old woman visited our hospital with chief com-
plaints of recent onset (within 2 weeks) of bilateral shoulder
and neck pain, bilateral hip pain, and morning stiffness lasting
4 h. Arms and thighs were tender to touch. Shoulder active
motion was grossly limited (EUL, grade 3). VAS-p and VAS-
ph were 7, and CRP and ESR levels were 6.95 mg/dl and
97mm/h, respectively. The white blood cell (WBC) count was
7,400/ml, and the PMR-AS was 48. Fat suppression magnetic
resonance imaging (MRI) of the shoulder showed evidence of
subacromial and subdeltoid bursitis, glenohumeral joint syno-
vitis, and biceps tenosynovitis.
The patient started with 15 mg/day of oral prednisolone. At
week 3 of treatment, the patient’s PMR-ASwas decreased to 9
and GC tapering was started by 2.5 mg every 2 weeks. At
week 5, the PMR-AS remained unchanged (9.7). Six milli-
grams per week of MTX was added to treatment with 10 mg/
day of prednisolone. Since the PMR-AS continued to worsen
(33.1 at week 13), the MTX dose was increased to 8 mg/
week. At week 17, PMR-AS was not improved (35.1)
and CRP was 6.73 mg/dl. TCZ therapy (8 mg/kg, every
4 weeks, intravenously) was introduced to the patient in
combination with MTX (8 mg/week) and prednisolone
(7.5 mg/day). One month later, the patient achieved
remission (PMR-AS, 0.1). Further three infusions of
TCZ were given. At week 29, prednisolone and MTX
was reduced to 5 mg/day and 6 mg/week, respectively.
The patient maintained remission for more than 8 months
with this regimen.
Case 2
A 67-year-old woman visited our hospital because of recent
onset (within 2 weeks) of bilateral shoulder and neck pain, and
morning stiffness lasting 4 h. The first physical examination
showed reduced range of motion of the shoulders and neck
(EUL, grade 3). Arms and thighs were tender to touch; VAS-p
and VAS-ph were 9; and CRP and ESR levels were 11.47 mg/
dl and 103mm/h, respectively. TheWBC count was 8,040/ml,
and the PMR-AS was 56.5. Fat suppression MRI of the
shoulder showed evidence of subacromial bursitis,
glenohumeral joint synovitis, and biceps tenosynovitis.
The patient started with 15 mg/day of oral prednisolone. At
week 3 of treatment, the patient’s clinical symptoms improved
with decreased CRP (1.5 mg/dl), and prednisolone tapering
was started by 2.5 mg every 2 weeks until 10mg/day. At week
5, the CRP level was 1.28, and it continued to decrease during
the next month. At week 11, however, the CRP level rose to
1.82 mg/dl and therefore SASP (1 g/day) was added to treat-
ment with 10 mg/day of prednisolone. At week 13, PMR
symptoms remained aggravated and CRP was increased to
6.59. Prednisolone was increased to 15 mg/day. SASP was
discontinued because of abnormal values of serum hepatic
enzymes. At week 17, the patient achieved remission (CRP,
0.1 mg/dl; PMR-AS, 0.5) and maintained remission with
5 mg/day of prednisolone for 3 months. At week 29, she
experienced a flare (PMR-AS, 11.3; CRP, 2.25 mg/dl). TCZ
therapy (8 mg/kg, every 4 weeks, intravenously) was added to
5 mg/day of prednisolone. One month later, the patient
achieved remission (PMR-AS, 0.1). An additional infusion
of TCZ was given. Prednisolone was then tapered off over
6 months.
Case 3
A 73-year-old woman consulted a neighboring clinic because
of recent onset (within 2 weeks) of bilateral shoulder and neck
pain. Since PMR was suspected, 10 mg/day of prednisolone
was prescribed. Two days later, the patient was referred to our
hospital for aggravation of symptoms. The patient complained
of bilateral shoulder, hip, and neck pain and morning stiffness
lasting 6 h. Active movements of the shoulders and neck were
markedly restricted (EUL, grade 3). Arms and thighs were
tender to touch; VAS-p and VAS-ph were both 10; and the
values of CRP and ESR were 14.95 mg/dl and 81 mm/h,
respectively. The WBC count was 16,200/ml, and the
PMR-AS was 74. Fat suppression MRI of the shoulder
showed evidence of glenohumeral joint synovitis and
biceps tenosynovitis.
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The patient started with 15 mg/day of oral prednisolone.
Since the patient’s symptoms were aggravated for 2 weeks of
this therapy (CRP, 14.99 mg/dl; PMR-AS, 97), TCZ therapy
was added (8 mg/kg, every 4 weeks) to treatment with 15 mg/
day of prednisolone. One month after the first TCZ infusion,
the CRP was 8.92 mg/dl and PMR-AS was 59. Because of a
suspected non-PMR diagnosis, we examined blood cultures,
gallium scintigraphy, computer tomography of the abdomen
and pelvis with contrast, and upper gastrointestinal endosco-
py, but we found no evidence of active infections or malig-
nancies. We also confirmed that there were no clinical symp-
toms or signs of GCA and then restarted TCZ therapy
(162 mg, every 2 weeks, subcutaneously) with 10 mg/day of
prednisolone. Prednisolone was tapered by 1 mg every month.
After six injections of TCZ, disease activity was still within
the median range (PMR-AS, 14) despite the normalization of
CRP. MTX (6 mg/week) was added to treatment with TCZ
and prednisolone (5 mg/day). Through 3 months of this treat-
ment, the patient achieved remission (PMR-AS, 1.1).
Literature review on TCZ treatment for PMR patients
By performing a search of the medical literature as of January
31, 2014 using the terms “polymyalgia rheumatica,” “toci-
lizumab,” and “anti-IL-6 receptor,” we identified 13 cases
where PMR patients were treated with TCZ alone or in com-
bination with GCs: five were pure PMR cases and eight were
GCA-associated PMR cases [15–21]. One patient with pure
PMR had unclassified aortitis without clinical manifestations
related to large-vessel vasculitis such as GCA or Takayasu
arteritis [19]. Clinical features and therapeutic outcomes of
these cases, including the three pure PMR cases in the present
study, are summarized in Table 2 (cases 1–8: pure PMR) and
Table 3 (cases 9–16: GCA-associated PMR).
In pure PMR cases, all patients except case 3 received
8 mg/kg of TCZ monthly. In case 3, the patient received a
subcutaneous TCZ injection (162 mg) every 2 weeks. One
patient (case 4) was newly diagnosed and had never received
GCs before starting TCZ therapy. Another patient responded
well to GC therapy but suffered from GC-related adverse
events (case 8). This patient showed MTX and etanercept
resistance. The remaining six patients were GC-resistant
cases. Cases 1 and 2 showed MTX and SASP resistance,
respectively. In cases 3 and 4, the patients had poor responses
to TCZ therapy (case 3, 4 months of combination therapy with
prednisolone; case 4, 2 months of monotherapy). In case 3,
however, the addition ofMTX resulted in remission. In case 4,
after the discontinuation of TCZ, the patient achieved remis-
sion by prednisolone alone. In case 1, the addition of TCZ to
treatment with MTX and prednisolone produced remission
within 1 month. In cases 2, 5, and 6, the addition of TCZ to
GC therapy markedly improved clinical symptoms and labo-
ratory data. The GC dose was successfully reduced during
TCZ therapy (cases 1–3 and 5–6). Two patients achieved
remission with TCZ monotherapy (cases 7 and 8).
In eight patients with GCA-associated PMR, seven were
treated with 8 mg/kg of TCZ monthly and one received
4 mg/kg monthly (case 12). Three cases were GC naive (cases
9, 13, and 14). Five patients achieved remission within






Age, median (IQR) (years) 65 (61.3–77.8) 73 (67–77) 0.49
Male/female 8/6 2/7 0.11
Duration of symptoms before therapy, median (IQR) (weeks) 2 (2–2) 2 (2–4) 0.33
C-reactive protein level, median (IQR) (mg/dl) 4.8 (4.0–9.9) 11.5 (8.0–13.6) 0.018
Erythrocyte sedimentation rate, median (IQR) (mm/h) 78.5 (51.3–82) 100 (81–103) 0.068
PMR activity score, median (IQR) 23.8 (22.2–35.5) 48 (44.5–66) 0.0098
Patient’s pain assessment (VAS 0–10), median (IQR) 6.5 (4.3–7.8) 9 (7–10) 0.014
Physician’s global assessment (VAS 0–10), median (IQR) 6 (4.3–7) 9 (7–10) 0.033
Morning stiffness (min), median (IQR) 60 (60–120) 240 (120–300) 0.019
EUL (0–3), median (IQR) 1 (1–2) 3 (2–3) 0.0026
Peripheral arthritisb, numbers of patients (%) 0 4 (44.4) 0.014
Body weight (kg), median (mean±SD) 55.4±9.6 53.1±10.3 0.30
Duration to first remission (weeks), median (IQR) 2 (2–2) 30 (26–34) <0.0005
PMR polymyalgia rheumatica, GC glucocorticoid, IQR interquartile range, VAS visual analog score, EUL ability to elevate the upper limbs
a Clinical characteristics of GC responders and GC-resistant patients were compared using theMann-WhitneyU test for continuous variables and χ2 test
and Fisher’s exact probability test for categorical variables
b Peripheral arthritis includes knees, wrists, ankles, elbows, hands, and feet
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3 months of TCZ therapy combined with prednisolone and
tolerated the GC tapering during the TCZ use (cases 10–12,
15, and 16). Among these, two patients successfully
discontinued prednisolone (cases 11 and 15). Two patients
achieved remission with TCZmonotherapy (cases 13 and 14).
The remaining one had partial responses to six infusions of
TCZ without GC (case 9).
These data suggest the utility of TCZ as a GC-sparing agent
or as monotherapy for PMR patients. The introduction of TCZ
to GC-resistant PMR patients may reduce cumulative GC
doses or even replace GC therapy, which may result in a
decreased risk of GC-related adverse events. It is unclear
whether TCZ may be the first-line agent for the treatment of
PMR. Given the high cost of TCZ therapy, GC therapy
continues to be the first choice for PMR patients.
Discussion
IL-6 is produced at the site of inflammation and plays a key
role in the acute phase response. The correlation of serum
levels of IL-6 and PMR activity during GC therapy has been
examined over the past two decades. The majority of studies
have indicated that IL-6 levels are significantly higher in
active PMR patients compared with those in healthy controls
[22–29] and that the administration of GCs significantly re-
duces IL-6 levels [22–25, 27–29]. Serum levels of IL-6 in
PMR patients were significantly increased at the time of
clinical relapse compared with those in patients in remission
[30]. Several studies showed that persistently elevated levels
of serum IL-6 during GC therapy are significantly associated
with an increased risk of relapse and recurrence of PMR
activity as well as a prolonged course with a need for in-
creased prednisolone dose [5, 31]. A high level of serum
soluble IL-6 receptor was identified as a potential prognostic
marker for relapse in PMR patients [7]. These data support the
idea that IL-6 is an important mediator in the pathogenesis of
PMR. Through a search of the Medline database be-
tween 1980 and April 2008, Martinez-Taboada et al.
indicated that PMR is characterized by a hyperproduc-
tion of IL-6 and that GC therapy is followed by a
significant decrease in serum IL-6 [32].
In the present study, the five patients with GC-resistant
PMR responded well to the addition of 6 to 8 mg/week of
MTX to GC therapy and maintained remission for more than
6 months with or without 5 mg/day prednisolone, although
one patient failed to achieve remission with the addition of
MTX (case 1 in Table 2). To examine the GC-sparing effect of
MTX, two randomized, double-blinded, placebo-controlled
trials were performed. One study reported that the concomi-
tant use of MTX in newly diagnosed PMR patients was
associated with shorter GC treatment and GC sparing, when
given for at least 1 year at a dose of at least 10 mg/day [33]. A
long-term follow-up of these patients indicated thatMTX does
not decrease the incidence of GC-related adverse events,
however [34]. Another study indicated that there were no
differences between the MTX and placebo groups in active,
untreated PMR patients in terms of time to achieve remission,
duration of remission, number of flares, cumulative GC doses,
or GC-related adverse events [35]. However, these studies
may have included a considerable number of GC responders
(patients who respond well to GC therapy and tolerate GC
reduction without the use of MTX), which may lead to an
underestimation of the GC-sparing effect of MTX. The GC-
sparing effect of MTX should be further examined in random-
ized, controlled studies for GC-resistant PMR patients.
Several pretreatment parameters have been suggested as
the risk factors for the development of GC resistance.
Relapses may occur more frequently in women [36, 37], and
female sex and increased age were reported to be risk factors
for requiring longer GC therapy [38]. In addition, increased
levels of inflammatory parameters such as CRP and ESR at
baseline have been reported as risk factors for relapse/
recurrence and prolonged GC therapy [31, 37–40].
However, some studies reported that there were no clinical
or laboratory features significantly associated with relapses or
prolonged GC therapy [41–43]. Using multivariate analysis,
Cimmino et al. recently indicated that the only factor
predicting a good response to GCs is low weight, when
PMR patients are treated with an initial dose of 12.5 mg/day
prednisolone (responders 67.4 kg vs. non-responders 78.5 kg)
[44]. In our cohort, there was no difference in body weight
between the two groups, which may be explained by the lower
mean body weight of our patients (55.1 vs. 53.1 kg).
In the present study, the pretreatment values of PMR-AS
and its five components, especially EUL, were significantly
higher in GC-resistant patients. The PMR-AS, which was
developed by Leeb and Bird based on a core set of five
variables composing EULAR response criteria for PMR
(CRP, VAS-p, VAS-ph, MST, and EUL), provides an easily
applicable and valid tool for monitoring PMR activity in
everyday practice. In combination with the EULAR response
criteria, it provides a better description of treatment response
[14, 45]. In a prospective cohort study, Binard et al. showed
that a diagnosis of disease flare is strongly associated with
PMR-AS values ≥9.35 and their changes between two visits to
the physician ≥6.6 [46]. The changes of disease activity over
time seem even more relevant and perform better than the
absolute PMR-AS values when predicting a need of the
GC dose increase [46, 47]. These studies showed the
utility of this scoring system in monitoring PMR activ-
ity and making clinical and therapeutic decisions for
individual patients. In addition to monitoring PMR ac-
tivity, our findings have suggested that these parameters
may be helpful in predicting the development of GC
resistance in individual patients at the time of diagnosis
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and therefore identifying patients who will require ad-
ditional therapy for the management of PMR.
Conclusion
Although GCs are still the mainstay in PMR treatment, the use
of alternative immunosuppressive agents should be consid-
ered for GC-resistant patients in order to minimize the cumu-
lative GC exposure. Given the involvement of IL-6 in PMR
pathogenesis, TCZ may be one of the most promising thera-
peutic options for this inflammatory disorder. The pretreat-
ment values of PMR-AS and its componentsmay be helpful in
predicting which patient is most at risk for developing GC
resistance. Regarding the prognostic utility of baseline PMR-
AS values and the utility of TCZ therapy for GC-resistant
PMR, we require careful scrutiny in large-scale follow-up
studies where patients are treated according to standardized
guidelines for PMR management.
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